Session » Antiphospholipid Syndrome - Poster I

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1065

A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score

9:00AM-11:00AM: Abstract Number: 1063

A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 1071

Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations

9:00AM-11:00AM: Abstract Number: 1060

Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports

9:00AM-11:00AM: Abstract Number: 1073

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results

9:00AM-11:00AM: Abstract Number: 1072

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients

9:00AM-11:00AM: Abstract Number: 1064

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 1066

History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 1067

History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 1061

Identifying Clinical and Epidemiological Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese APS Patients

9:00AM-11:00AM: Abstract Number: 1062

Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy

9:00AM-11:00AM: Abstract Number: 1070

Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients

9:00AM-11:00AM: Abstract Number: 1059

Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy

9:00AM-11:00AM: Abstract Number: 1068

Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years

9:00AM-11:00AM: Abstract Number: 1069

The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis

9:00AM-11:00AM: Abstract Number: 1074

The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].